Trial Profile
Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2016
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms AC-ANGIOPREDICT
- 16 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Apr 2013 New trial record